Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Florida
Bristol-Myers Squibb
Daiichi Sankyo
Alliance for Clinical Trials in Oncology
University of Arizona
AstraZeneca
BicycleTx Limited
NRG Oncology
Mayo Clinic
National Cancer Center, Korea
Columbia University
University Health Network, Toronto
Brown University
Hospital Centre Biel/Bienne
Hoosier Cancer Research Network
Zhujiang Hospital
Fudan University